Hoth Therapeutics (NASDAQ:HOTH) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Hoth Therapeutics (NASDAQ:HOTH) released its earnings results on Thursday. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07, Zacks reports.

Hoth Therapeutics Price Performance

Shares of HOTH stock opened at $1.03 on Friday. The company has a market cap of $7.11 million, a PE ratio of -0.78 and a beta of 0.84. Hoth Therapeutics has a 1 year low of $0.58 and a 1 year high of $3.80. The stock’s 50 day simple moving average is $1.13 and its two-hundred day simple moving average is $1.01.

Analyst Ratings Changes

HOTH has been the topic of a number of recent analyst reports. D. Boral Capital reissued a “buy” rating and set a $5.00 price target on shares of Hoth Therapeutics in a report on Monday, March 10th. HC Wainwright reissued a “buy” rating and set a $4.00 price target on shares of Hoth Therapeutics in a research note on Thursday, January 23rd.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.